Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...

Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

Oncology nurses are familiar with the concept of financial toxicity, which refers to the significant financial burden cancer ...

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose ...

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time ...

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

C, BSN, RN, discussed taking advantage of available resources to provide comprehensive care for patients with breast cancer.

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease ...

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for ...

Panelists discuss how they maintain treatment adherence through digital health apps, calendar reminders, and symptom journals while working closely with their care teams to address uncertainties and ...